Vertex Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6
Vertex Pharmaceuticals ha un patrimonio netto totale di $15.6B e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $22.2B e $6.6B. L'EBIT di Vertex Pharmaceuticals è $4.2B rendendo il suo rapporto di copertura degli interessi -6.9. Ha liquidità e investimenti a breve termine pari a $6.5B.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | -6.9x |
| Contanti | US$6.52b |
| Patrimonio netto | US$15.63b |
| Totale passività | US$6.61b |
| Totale attività | US$22.24b |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $9.8B ) di VRTX superano le sue passività a breve termine ( $4.0B ).
Passività a lungo termine: Le attività a breve termine di VRTX ( $9.8B ) superano le sue passività a lungo termine ( $2.6B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: VRTX è esente da debiti.
Riduzione del debito: VRTX non aveva debiti 5 anni fa.
Copertura del debito: VRTX non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.
Copertura degli interessi: VRTX non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.